A Phase 3 Study of MEDI-524 (Motavizumab), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prevention of RSV Disease Among Native American Infants in the Southwestern United States
Latest Information Update: 06 Jan 2022
At a glance
- Drugs Motavizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- 05 May 2011 Status changed from recruiting to completed.
- 14 May 2008 Results are presented at the Pediatric Academic Societies (PAS) Annual Meeting.
- 27 Dec 2007 Status changed from in progress to recruiting.